Galectin-3 in septic acute kidney injury: a translational study.
APACHE
Acute Kidney Injury
/ blood
Aged
Animals
Blood Proteins
/ analysis
Cecum
/ abnormalities
Chi-Square Distribution
China
Creatinine
/ analysis
Disease Models, Animal
Female
Galectin 3
/ analysis
Galectins
/ analysis
Humans
Intensive Care Units
/ organization & administration
Interleukin-6
/ analysis
Ligation
/ adverse effects
Logistic Models
Male
Middle Aged
Prospective Studies
Rats
Rats, Sprague-Dawley
/ injuries
Sepsis
/ blood
Survival Analysis
Acute kidney injury
Galectin-3
Sepsis
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
18 03 2021
18 03 2021
Historique:
received:
28
12
2020
accepted:
08
03
2021
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
7
9
2021
Statut:
epublish
Résumé
Galectin-3 (Gal-3) is a pleiotropic glycan-binding protein shown to be involved in sepsis and acute kidney injury (AKI). However, its role has never been elucidated in sepsis-associated AKI (S-AKI). We aimed to explore Gal-3's role and its potential utility as a therapeutic target in S-AKI. In 57 patients admitted to the intensive care unit (ICU) with sepsis, serum Gal-3 was examined as a predictor of ICU mortality and development of AKI. In a rat model of S-AKI induced by cecal ligation and puncture (CLP), 7-day mortality and serum Gal-3, Interleukin-6 (IL-6), and creatinine were examined at 2, 8, and 24 hours (h) post-CLP. Two experimental groups received the Gal-3 inhibitor modified citrus pectin (P-MCP) at 400 mg/kg/day and 1200 mg/kg/day, while the control group received water only (n = 18 in each group). Among 57 patients, 27 developed AKI and 8 died in the ICU. Serum Gal-3 was an independent predictor of AKI (OR = 1.2 [95% CI 1.1-1.4], p = 0.01) and ICU mortality (OR = 1.4 [95% CI 1.1-2.2], p = 0.04) before and after controlling for age, AKI, and acute physiology and chronic health evaluation (APACHE II) score. In the CLP rat experiment, serum Gal-3 peaked earlier than IL-6. Serum Gal-3 was significantly lower in both P-MCP groups compared to control at 2 h post-CLP (400 mg: p = 0.003; 1200 mg: p = 0.002), and IL-6 was significantly lower in both P-MCP groups at all time points with a maximum difference at 24 h post-CLP (400 mg: p = 0.015; 1200 mg: p = 0.02). In the Gal-3 inhibitor groups, 7-day mortality was significantly reduced from 61% in the control group to 28% (400 mg P-MCP: p = 0.03) and 22% (1200 mg P-MCP: p = 0.001). Rates of AKI per RIFLE criteria were significantly reduced from 89% in the control group to 44% in both P-MCP groups (400 mg: p = 0.007; 1200 mg: p = 0.007). This translational study demonstrates the importance of Gal-3 in the pathogenesis of S-AKI, and its potential utility as a therapeutic target.
Sections du résumé
BACKGROUND
Galectin-3 (Gal-3) is a pleiotropic glycan-binding protein shown to be involved in sepsis and acute kidney injury (AKI). However, its role has never been elucidated in sepsis-associated AKI (S-AKI). We aimed to explore Gal-3's role and its potential utility as a therapeutic target in S-AKI.
METHODS
In 57 patients admitted to the intensive care unit (ICU) with sepsis, serum Gal-3 was examined as a predictor of ICU mortality and development of AKI. In a rat model of S-AKI induced by cecal ligation and puncture (CLP), 7-day mortality and serum Gal-3, Interleukin-6 (IL-6), and creatinine were examined at 2, 8, and 24 hours (h) post-CLP. Two experimental groups received the Gal-3 inhibitor modified citrus pectin (P-MCP) at 400 mg/kg/day and 1200 mg/kg/day, while the control group received water only (n = 18 in each group).
RESULTS
Among 57 patients, 27 developed AKI and 8 died in the ICU. Serum Gal-3 was an independent predictor of AKI (OR = 1.2 [95% CI 1.1-1.4], p = 0.01) and ICU mortality (OR = 1.4 [95% CI 1.1-2.2], p = 0.04) before and after controlling for age, AKI, and acute physiology and chronic health evaluation (APACHE II) score. In the CLP rat experiment, serum Gal-3 peaked earlier than IL-6. Serum Gal-3 was significantly lower in both P-MCP groups compared to control at 2 h post-CLP (400 mg: p = 0.003; 1200 mg: p = 0.002), and IL-6 was significantly lower in both P-MCP groups at all time points with a maximum difference at 24 h post-CLP (400 mg: p = 0.015; 1200 mg: p = 0.02). In the Gal-3 inhibitor groups, 7-day mortality was significantly reduced from 61% in the control group to 28% (400 mg P-MCP: p = 0.03) and 22% (1200 mg P-MCP: p = 0.001). Rates of AKI per RIFLE criteria were significantly reduced from 89% in the control group to 44% in both P-MCP groups (400 mg: p = 0.007; 1200 mg: p = 0.007).
CONCLUSIONS
This translational study demonstrates the importance of Gal-3 in the pathogenesis of S-AKI, and its potential utility as a therapeutic target.
Identifiants
pubmed: 33736691
doi: 10.1186/s13054-021-03538-0
pii: 10.1186/s13054-021-03538-0
pmc: PMC7977587
doi:
Substances chimiques
Blood Proteins
0
Galectin 3
0
Galectins
0
Il6 protein, rat
0
Interleukin-6
0
LGALS3 protein, human
0
Lgals3 protein, rat
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109Références
Crit Care Med. 2017 Mar;45(3):438-445
pubmed: 28079606
Semin Nephrol. 2019 Jan;39(1):96-106
pubmed: 30606411
Immunotherapy. 2016 Jul;8(8):959-70
pubmed: 27381687
Front Immunol. 2020 Aug 18;11:2069
pubmed: 32973815
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
PLoS One. 2016 Nov 9;11(11):e0166272
pubmed: 27829066
Crit Care Med. 2014 Apr;42(4):e270-8
pubmed: 24335444
Ann Intensive Care. 2017 Dec;7(1):27
pubmed: 28271449
J Infect. 2018 Nov;77(5):391-397
pubmed: 30226191
JAMA. 2005 Aug 17;294(7):813-8
pubmed: 16106006
Eur Rev Med Pharmacol Sci. 2016;20(2):345-54
pubmed: 26875907
Immunol Rev. 2009 Jul;230(1):160-71
pubmed: 19594635
Biosci Rep. 2018 Dec 18;38(6):
pubmed: 30455396
Transpl Int. 2008 Oct;21(10):999-1007
pubmed: 18657091
Crit Care. 2008;12(2):R47
pubmed: 18402655
J Pathol. 1999 Mar;187(4):481-9
pubmed: 10398110
Crit Care Explor. 2020 Aug 10;2(8):e0178
pubmed: 32832913
Nutrients. 2019 Nov 01;11(11):
pubmed: 31683865
PLoS One. 2013;8(3):e59616
pubmed: 23527230
Crit Care. 2007;11(2):R49
pubmed: 17448250
Clin Chim Acta. 2015 May 20;445:155-60
pubmed: 25850080
Intensive Care Med. 2015 Aug;41(8):1411-23
pubmed: 26162677
Intensive Care Med. 2011 Feb;37(2):241-8
pubmed: 21152901
J Crit Care. 2016 Aug;34:38-45
pubmed: 27288608
Clin J Am Soc Nephrol. 2007 May;2(3):431-9
pubmed: 17699448
Inflamm Regen. 2020 Oct 5;40:24
pubmed: 33024459
Am J Pathol. 2008 Feb;172(2):288-98
pubmed: 18202187
Crit Care Med. 2012 Feb;40(2):538-43
pubmed: 21926582
APMIS. 2011 Feb;119(2):155-63
pubmed: 21208283
JAMA. 2016 Feb 23;315(8):775-87
pubmed: 26903336
Kidney Int. 2018 Jan;93(1):252-259
pubmed: 28865675
J Am Soc Nephrol. 2015 Sep;26(9):2213-21
pubmed: 25568176
JACC Heart Fail. 2015 Jan;3(1):59-67
pubmed: 25458174
Crit Care. 2015 May 06;19:223
pubmed: 25944130
Am J Physiol Renal Physiol. 2015 Mar 1;308(5):F500-9
pubmed: 25503732
J Clin Med. 2020 Jun 21;9(6):
pubmed: 32575833
Am J Nephrol. 2016;43(5):305-17
pubmed: 27166158
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Transplantation. 2012 Mar 15;93(5):477-84
pubmed: 22306573
JACC Basic Transl Sci. 2019 Oct 28;4(6):717-732
pubmed: 31709320
Am J Pathol. 2000 Sep;157(3):815-23
pubmed: 10980121
Arch Intern Med. 2007 Aug 13-27;167(15):1655-63
pubmed: 17698689
Sci Rep. 2019 Mar 18;9(1):4777
pubmed: 30886220
Circulation. 2007 Feb 6;115(5):654-7
pubmed: 17283280
BMC Nephrol. 2018 Oct 20;19(1):280
pubmed: 30342486
J Hypertens. 2018 Feb;36(2):368-376
pubmed: 28858976
Chest. 2019 Mar;155(3):626-638
pubmed: 30266628
Inflamm Res. 2009 Jul;58(7):385-93
pubmed: 19262987
Eur J Clin Microbiol Infect Dis. 2013 Dec;32(12):1605-10
pubmed: 23828453
Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1324-31
pubmed: 26195505
J Am Soc Nephrol. 2013 Sep;24(9):1470-7
pubmed: 23766533
Biochim Biophys Acta. 2006 Apr;1760(4):616-35
pubmed: 16478649
PLoS One. 2011 Apr 08;6(4):e18683
pubmed: 21494626